Immutep Limited - American Depositary Shares (IMMP)
2.5800
-0.0500 (-1.90%)
NASDAQ · Last Trade: Dec 13th, 10:52 AM EST
Detailed Quote
Previous Close
2.630
Open
2.630
Bid
2.520
Ask
2.590
Day's Range
2.480 - 2.650
52 Week Range
1.320 - 3.530
Volume
418,336
Market Cap
1.93B
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,576,450
Chart
About Immutep Limited - American Depositary Shares (IMMP)
Immutep Ltd is a biotechnology company that focuses on developing innovative immunotherapy treatments for cancer and autoimmune diseases. The company is primarily engaged in the research and development of products that harness the power of the immune system to better target and eliminate cancer cells. Immutep's pipeline includes both monoclonal antibodies and other therapeutic agents designed to enhance immune response, with an emphasis on delivering effective treatments for patients with unmet medical needs. Through partnerships and collaborations, Immutep aims to pioneer new approaches to cancer therapy and improve patient outcomes. Read More
SurgePays, Inc. (NASDAQ: SURG), a rapidly expanding technology and telecommunications company serving the prepaid and underserved consumer markets, released an update highlighting its multi-vertical growth strategy designed to scale revenue across wireless, fintech, and retail partner ecosystems. The company confirmed that Lifeline Wireless remains the fastest path to near-term profitability, while its prepaid brand LinkUp Mobile, HERO MVNE services , prepaid fintech top-up platform , and ClearLine SaaS retail media network form the backbone of its 2026 and long-term expansion plans.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Sydney, Australia/Hyderabad, India, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, and along with its subsidiaries, hereafter referred to as “Dr. Reddy’s”), today announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy’s Laboratories SA, have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China.
SYDNEY, AUSTRALIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a patient enrolment update for the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and chemotherapy as first line treatment for advanced or metastatic non-small cell lung cancer (1L NSCLC).
SYDNEY, AUSTRALIA, May 15, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that a 60.8% response rate and 90.2% disease control rate, according to RECIST1.1, has been achieved in the investigator-initiated INSIGHT-003 trial as of the data-cut off date of 06 May 2025. INSIGHT-003 is evaluating eftilagimod alpha (efti) in combination with the anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) and doublet chemotherapy as first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer (1L NSCLC).
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer patients, with no new safety concerns.
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.
